Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Prof. Dr. med. Anca-L. Grosu

Contact:

Chair
Department for Radiation Oncology
Robert-Koch-Straße 3
University Medical Center Freiburg
79106 Freiburg
Phone +49 761 270 94610
Fax +49 761 270 94720
anca.grosu@uniklinik-freiburg.de
http://www.uniklinik-freiburg.de/strahlenklinik.html

Current Positions:

  • Chair of the Department for Radiology Oncology, University Medical Center Freiburg
  • Deputy Speaker of the German  Consortium for Translational Cancer Research (DKTK), partner site Freiburg, University Medical Center Freiburg
  • Adjunct Professor, Ohio State University, USA
  • Member of the Executive Committee of the German Neurooncology Working Group (NOA)
  • Member of the Executive Board of the Comprehensive Cancer Center, University Hospital Freiburg (CCCF)
  • Member of the Senate of the Albert-Ludwigs-University Freiburg
  • Advisory Board Member of the Comprehensive Cancer Center Freiburg Graz (CCC Graz), Austria
  • Member of the International Association of Surgeons, Gastroenterologistst & Oncologists
  • Chair of the Hanns-Langendorff Foundation Committee
  • Member of the Independent Expert Panel of the German Society of Radiation Oncology (DEGRO)
  • Deputy of the Equal Opportunities Officer, Albert-Ludwigs-University Freiburg

 

Research Focus:

  • Topic: Innovative IT Infrastructures: RadPlanBio
    Biological imaging for radiation therapy planning and monitoring
  • Topic: Biological Individualization of Radiation Oncology

Clinical Focus:

Neurooncology, Head and Neck Cancer, Prostate Cancer

DKTK Research Topics

  • RadPlanBio-platform (RadiationDosePlan-Image/Biomarker-Outcome-platform) – with the associated studies
  • Biological individualization of radiation oncology
  • Radiobiological profiling for biologically stratified radiochemotherapy of HNSCC: A DKTK multicenter retrospective / prospective trial
  • DKTK-RadPlanBio infrastructure: (glioma/rectum)
  • HERACLES - Response prediction of stereotactic radiotherapy in hepatocellular carcinoma

Working Group Members DKTK:

Prof. Dr. med. Gabriele Niedermann    
PD Dr. med. Thomas Brunner
Prof. Dr. med. Ursula Nestle
Prof. Dr. med. Michael Henke
Dr. med. Sonja Adebahr    
Melanie Avlar    
Hua Jing    
Lahoti Jayashree

Research Website http://www.uniklinik-freiburg.de/strahlenklinik/forschung.html

 

DKTK Publications: 2015-2017

Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiotherapy and Oncology [Internet]. Mai 2017 [zitiert 7. Juni 2017]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0167814017303481

Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL. Comparison of 68 Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017;7(1):228–37.

 Wieser G, Popp I, Christian Rischke H, Drendel V, Grosu A-L, Bartholomä M, Weber WA, Mansi R, Wetterauer U, Schultze-Seemann W, Meyer PT, Jilg CA. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging [Internet]. 18. April 2017 [zitiert 19. April 2017]; Verfügbar unter: link.springer.com/10.1007/s00259-017-3702-8

Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Høyer M, Ricardi U, Sterzing F, Guckenberger M. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiotherapy and Oncology [Internet]. Februar 2017 [zitiert 21. Februar 2017]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0167814017300087

Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL, Brunner TB. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer: A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlentherapie und Onkologie [Internet]. 30. Januar 2017 [zitiert 21. Februar 2017]; Verfügbar unter: link.springer.com/10.1007/s00066-017-1099-8

Balermpas P, Rödel F, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Sak A, Stuschke M, Gkika E, Grosu A-L, Abdollahi A, Debus J, Stangl S, Ganswindt U, Belka C, Pigorsch S, Multhoff G, Combs SE, Welz S, Zips D, Lim SY, Rödel C, Fokas E, for the DKTK-ROG. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG): PD-1/PD-L1 axis and HPV in patients with head and neck cancer after adjuvant CRT. International Journal of Cancer [Internet]. 19. Mai 2017 [zitiert 7. Juni 2017]; Verfügbar unter: doi.wiley.com/10.1002/ijc.30770

Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, Salman N, Drendel V, Werner M, Mix M, Meyer PT, Grosu AL. 68 Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics. 2016;6(10):1619–28.

Zamboglou C, Rischke H-C, Meyer PT, Knobe S, Volgeova-Neher N, Kollefrath M, Jilg CA, Grosu AL, Baltas D, Kroenig M. Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. Journal of Contemporary Brachytherapy. 2016;3:241–8.

Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Jöhrens K, Weichert W, Linge A, Lohaus F, Krause M, Neumann K, Endris V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baumann M. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. European Journal of Cancer. April 2016;57:78–86. 

Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. International Journal of Radiation Oncology*Biology*Physics [Internet]. September 2016 [zitiert 23. November 2016]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0360301616332096

Popp I, Grosu AL, Niedermann G, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiotherapy and Oncology [Internet]. August 2016 [zitiert 18. August 2016]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0167814016312051

Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu A-L. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer [Internet]. Dezember 2016 [zitiert 18. Oktober 2016];16(1). Verfügbar unter: bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2806-z

Linge A, Lohaus F, Löck S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jütz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Grosu A-L, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology [Internet]. November 2016 [zitiert 5. Dezember 2016]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0167814016343833

Linge A, Lock S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, Ju tz M, Abdollahi A, Debus J, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Ro del C, Avlar M, Grosu A-L, Bayer C, Belka C, Pigorsch S, Combs SE, Welz S, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Baumann M, Krause M, for the DKTK-ROG. Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research. 1. Juni 2016;22(11):2639–49.

Jing H, Weidensteiner C, Reichardt W, Gaedicke S, Zhu X, Grosu A-L, Kobayashi H, Niedermann G. Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics. 2016;6(6):862–74.

Fennell J, Scholber J, Grosu A-L, Volegova-Neher N, Henne K, Langer M, Meyer PT, Gitsch G, Bartl N. MRI and FDG-PET/CT imaging in gynecological malignancies: the radiation oncology perspective. Q J Nucl Med Mol Imaging. Juni 2016;60(2):117–23.

Brunner TB. The rationale of combined radiotherapy and chemotherapy – Joint action of Castor and Pollux. Best Practice & Research Clinical Gastroenterology. August 2016;30(4):515–28.

Brunner TB, Seufferlein T. Chemoradiotherapy, the backbone of radiotherapy in gastrointestinal oncology. Best Practice & Research Clinical Gastroenterology. August 2016;30(4):511–3.

Bittner M-I, Wiedenmann N, Bucher S, Hentschel M, Mix M, Rücker G, Weber WA, Meyer PT, Werner M, Grosu A-L, Kayser G. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. Acta Oncologica. 3. September 2016;1–6.

Bilger A, Milanovic D, Lorenz H, Oehlke O, Urbach H, Schmucker M, Weyerbrock A, Nieder C, Grosu A-L. Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clinical Neurology and Neurosurgery. März 2016;142:81–6.

Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M, Grosu A-L. MRI versus (68)Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging. 23. November 2015;

Wiedenmann NE, Bucher S, Hentschel M, Mix M, Vach W, Bittner M-I, Nestle U, Pfeiffer J, Weber WA, Grosu AL. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiotherapy and Oncology [Internet]. September 2015 [zitiert 6. Oktober 2015]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0167814015004739

Chirindel A, Adebahr S, Schuster D, Schimek-Jasch T, Schanne DH, Nemer U, Mix M, Meyer P, Grosu A-L, Brunner T, Nestle U. Impact of 4D-18FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study. Radiotherapy and Oncology. Juni 2015;115(3):335–41.

Balermpas P, Rödel F, Rödel C, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Gkika E, Stuschke M, Avlar M, Grosu A-L, Abdollahi A, Debus J, Bayer C, Stangl S, Belka C, Pigorsch S, Multhoff G, Combs SE, Mönnich D, Zips D, Fokas E, for the DKTK-ROG. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer. Juli 2015;n/a-n/a.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. The British Journal of Radiology. Juli 2015;88(1051):20150036.

 

-- Logo: © dkfz.de

Prof. Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 49
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
++49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de

Dr. Anna Dost
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 77121
a.dost@dkfz-heidelberg.de